VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2015 | Advances in the management of follicular lymphoma in the frontline and relapsed settings

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses the development of management strategies for patients with follicular lymphoma. In the relapsed setting, promising novel therapeutic agents include the phosphoinositide 3-kinase inhibitors, idelalisib and duvelisib; the immunomodulatory agent, lenalidomide; the anti-CD20 monoclonal antibody, obinutuzumab; the Bcl-2 inhibitor, venetoclax; and antibody-drug conjugates. In the frontline setting, promising novel therapeutic approaches include a combination of lenalidomide and the anti-CD20 monoclonal antibody, rituximab.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter